LGALS1 and neoplasm: In addition to restoring enzalutamide sensitivity, our findings show that Gal-1 inhibition exerts significant anti-tumor effects independent of drug resistance, suggesting that Gal-1’s role in prostate cancer extends beyond modulating drug resistance.